Skip to main navigation Skip to search Skip to main content

Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models

  • Nicha Wongjarupong
  • , Gabriela M. Negron-Ocasio
  • , Roongruedee Chaiteerakij
  • , Benyam D. Addissie
  • , Essa A. Mohamed
  • , Kristin C. Mara
  • , William S. Harmsen
  • , J. Paul Theobald
  • , Brian E. Peters
  • , Joseph G. Balsanek
  • , Melissa M. Ward
  • , Nasra H. Giama
  • , Sudhakar K. Venkatesh
  • , Denise M. Harnois
  • , Michael R. Charlton
  • , Hiroyuki Yamada
  • , Alicia Algeciras-Schimnich
  • , Melissa R. Snyder
  • , Terry M. Therneau
  • , Lewis R. Roberts

Research output: Contribution to journal › Review article › peer-review

Abstract

AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma (HCC) patients after liver transplant. METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3), and des-gamma-carboxyprothrombin (DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios (HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42 (1.18-5.00), 1.86 (0.98-3.52), and 2.83 (1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48 (1.15-1.91) and 1.59 (1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45 (1.06-1.98) and 1.38 (1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65, 0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant (S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter (S-LAD).

Original languageEnglish (US)
Pages (from-to)1321-1331
Number of pages11
JournalWorld journal of gastroenterology
Volume24
Issue number12
DOIs
StatePublished - Mar 28 2018

Bibliographical note

Publisher Copyright:
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • AFP-L3
  • Alpha-fetoprotein
  • BALAD
  • BALAD-2
  • Des-gamma-carboxyprothrombin
  • Hepatocellular carcinoma
  • Liver transplant
  • Outcome
  • Recurrence

Fingerprint

Dive into the research topics of 'Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models'. Together they form a unique fingerprint.

Cite this